Literature DB >> 7844671

Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course.

G Parenti1, G Sebastio, P Strisciuglio, B Incerti, C Pecoraro, L Terracciano, G Andria.   

Abstract

STUDY
OBJECTIVE: To evaluate phenotypic variability of lysinuric protein intolerance in a cohort of nine Italian patients.
DESIGN: Retrospective analysis of patient records.
SUBJECTS: Nine Italian patients (seven independent families), all originating from southern Italy, observed during the last 14 years.
RESULTS: Some of the patients had unique clinical features, including bone marrow abnormalities featuring erythroblastophagocytosis (five patients) and clinical course and the outcome of the disease, have also been observed: respiratory involvement was present in five cases, with a lethal picture of "alveolar proteinosis" in one. Severe kidney involvement, with both glomerular and tubular damage and rapidly progressing to chronic renal failure, has been observed in one case.
CONCLUSION: Lysinuric protein intolerance may cause severe multisystem involvement, which requires early and careful monitoring. Some peculiar clinical findings observed in Italian patients point to a genetic heterogeneity of lysinuric protein intolerance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844671     DOI: 10.1016/s0022-3476(95)70552-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

Review 1.  Chronic pancreatitis in branched-chain organic acidurias--a case of methylmalonic aciduria and an overview of the literature.

Authors:  Jan Marquard; Tarik El Scheich; Dirk Klee; Marcus Schmitt; Thomas Meissner; Ertan Mayatepek; Jun Oh
Journal:  Eur J Pediatr       Date:  2010-10-06       Impact factor: 3.183

2.  Lysine triggers apoptosis through a NADPH oxidase-dependent mechanism in human renal tubular cells.

Authors:  Daniela Verzola; Annamaria Famà; Barbara Villaggio; Maia Di Rocco; Alchiede Simonato; Elena D'Amato; Fabio Gianiorio; Giacomo Garibotto
Journal:  J Inherit Metab Dis       Date:  2012-03-09       Impact factor: 4.982

3.  Langerhans histiocytosis, haemophagocytic syndrome and Epstein-Barr virus infection.

Authors:  Lucien Corbeel
Journal:  Eur J Pediatr       Date:  2004-07-09       Impact factor: 3.183

4.  Growth hormone deficiency in a patient with lysinuric protein intolerance.

Authors:  Valentina Esposito; Teresa Lettiero; Simona Fecarotta; Gianfranco Sebastio; Giancarlo Parenti; Mariacarolina Salerno
Journal:  Eur J Pediatr       Date:  2006-06-15       Impact factor: 3.183

5.  Lung involvement in children with lysinuric protein intolerance.

Authors:  Sarah Valimahamed-Mitha; Laureline Berteloot; Héloise Ducoin; Chris Ottolenghi; Pascale de Lonlay; Jacques de Blic
Journal:  J Inherit Metab Dis       Date:  2014-10-22       Impact factor: 4.982

Review 6.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

7.  First reported case of lysinuric protein intolerance (LPI) in Lithuania, confirmed biochemically and by DNA analysis.

Authors:  Loreta Cimbalistiene; Willy Lehnert; Kirsi Huoponen; Vaidutis Kucinskas
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

8.  Renal Involvement in a French Paediatric Cohort of Patients with Lysinuric Protein Intolerance.

Authors:  C Nicolas; N Bednarek; V Vuiblet; O Boyer; A Brassier; P De Lonlay; L Galmiche; P Krug; V Baudouin; S Pichard; M Schiff; C Pietrement
Journal:  JIMD Rep       Date:  2015-11-26

Review 9.  Rare lung disease II: pulmonary alveolar proteinosis.

Authors:  Stephen C Juvet; David Hwang; Thomas K Waddell; Gregory P Downey
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

Review 10.  Pulmonary Alveolar Proteinosis Syndrome.

Authors:  Takuji Suzuki; Bruce C Trapnell
Journal:  Clin Chest Med       Date:  2016-06-17       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.